Literature DB >> 12243312

Hemoptysis: a retrospective analysis of 108 cases.

A Fidan1, S Ozdoğan, O Oruç, B Salepçi, Z Ocal, B Cağlayan.   

Abstract

A retrospective analysis of 108 patients admitted to the hospital for hemoptysis in the year 2000 was performed. The aim of the study was to clarify the etiologic distribution of hemoptysis and the relation of etiology to the severity and recurrence of it. Of the cases, 79 were men and 29 were women, and the mean age was 51.74 +/- 17.51. In 77 of the cases it was the first attack, while in 31 it was recurrent. According to the severity of hemoptysis, it was classified as "mild" (<30 cm3), "moderate" (30-100 cm3), "severe" (100-600 cm3) and "massive" (>600 cm3). Lung cancer was the leading cause of hemoptysis (34.3%) followed by bronchiectasis (25.0%), tuberculosis (17.6%), pneumonia (10.2%) and pulmonary embolism (4.6%). Statistical analysis by chi-square test revealed that most of the lung cancer patients had mild hemoptysis (odds ratio 3.5; P<0.05), and the most frequent etiology in recurrent hemoptysis was bronchiectasis (odds ratio 3.25; P=0.01). Most of the lung cancer patients were male (P=0.002). The two leading causes of hemoptysis in our study are similar to many previous reports. The high rate of tuberculosis in our study is probably due to the high prevalence of tuberculosis in our country.

Entities:  

Mesh:

Year:  2002        PMID: 12243312     DOI: 10.1053/rmed.2002.1359

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  12 in total

1.  Pulmonary resection in the treatment of life-threatening hemoptysis.

Authors:  Hakan Kiral; Serdar Evman; Cagatay Tezel; Levent Alpay; Tunc Lacin; Volkan Baysungur; Irfan Yalcinkaya
Journal:  Ann Thorac Cardiovasc Surg       Date:  2015-03-02       Impact factor: 1.520

2.  Alarm symptoms in early diagnosis of cancer in primary care: cohort study using General Practice Research Database.

Authors:  Roger Jones; Radoslav Latinovic; Judith Charlton; Martin C Gulliford
Journal:  BMJ       Date:  2007-05-10

3.  Risk factors of severe hemoptysis in patients with fungus ball.

Authors:  Tae Hoon Kim; Hyun Jung Koo; Chae-Man Lim; Sang-Bum Hong; Jin Won Huh; Kyung Wook Jo; Tae Sun Shim; Woo Sung Kim; Younsuck Koh
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

4.  Analysis of patients with hemoptysis in a tertiary referral hospital.

Authors:  Bo Ram Lee; Jin Yeong Yu; Hee Jung Ban; In Jae Oh; Kyu Sik Kim; Yong Soo Kwon; Yu Il Kim; Young Chul Kim; Sung Chul Lim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2012-08-31

Review 5.  Approach to Hemoptysis in the Modern Era.

Authors:  Sébastien Gagnon; Nicholas Quigley; Hervé Dutau; Antoine Delage; Marc Fortin
Journal:  Can Respir J       Date:  2017-12-21       Impact factor: 2.409

6.  Risk of cancer in patients with epistaxis and haemoptysis.

Authors:  Anne G Ording; Katalin Veres; Dóra K Farkas; Kasper Adelborg; Henrik T Sørensen
Journal:  Br J Cancer       Date:  2018-02-20       Impact factor: 7.640

Review 7.  2018 Korean Clinical Imaging Guideline for Hemoptysis.

Authors:  Mi-Jin Kang; Jin Hwan Kim; Yoon Kyung Kim; Hyun Joo Lee; Kyung Min Shin; Jung Im Kim; Hyun Ju Lee; Kyung Hyun Do; Hwan Seok Yong; Sol Ji Choi; Miyoung Choi; Jung Im Jung
Journal:  Korean J Radiol       Date:  2018-08-06       Impact factor: 3.500

8.  Is investigation of patients with haemoptysis and normal chest radiograph justified?

Authors:  M Thirumaran; R Sundar; I M Sutcliffe; D C Currie
Journal:  Thorax       Date:  2009-05-19       Impact factor: 9.139

9.  Haemoptysis as a prognostic factor in lung adenocarcinoma after curative resection.

Authors:  P Hu; G Wang; H Cao; H Ma; P Sui; J Du
Journal:  Br J Cancer       Date:  2013-08-20       Impact factor: 7.640

10.  Is atmospheric pressure change an Independent risk factor for hemoptysis?

Authors:  Omer Araz; Elif Yilmazel Ucar; Metin Akgun; Yener Aydin; Mehmet Meral; Leyla Saglam; Hasan Kaynar; Ali Metin Gorguner
Journal:  Pak J Med Sci       Date:  2014-05       Impact factor: 1.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.